FI3283058T3 - Ribosiklibitabletti - Google Patents

Ribosiklibitabletti Download PDF

Info

Publication number
FI3283058T3
FI3283058T3 FIEP16718020.7T FI16718020T FI3283058T3 FI 3283058 T3 FI3283058 T3 FI 3283058T3 FI 16718020 T FI16718020 T FI 16718020T FI 3283058 T3 FI3283058 T3 FI 3283058T3
Authority
FI
Finland
Prior art keywords
coating
tablet
silica
colloidal
ribociclib
Prior art date
Application number
FIEP16718020.7T
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Bindhumadhavan Gururajan
Arnaud Grandeury
Rui Costa
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI3283058(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of FI3283058T3 publication Critical patent/FI3283058T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FIEP16718020.7T 2015-04-16 2016-04-14 Ribosiklibitabletti FI3283058T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562148240P 2015-04-16 2015-04-16
PCT/IB2016/052136 WO2016166703A1 (en) 2015-04-16 2016-04-14 Ribociclib tablet

Publications (1)

Publication Number Publication Date
FI3283058T3 true FI3283058T3 (fi) 2023-03-01

Family

ID=55806565

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP16718020.7T FI3283058T3 (fi) 2015-04-16 2016-04-14 Ribosiklibitabletti

Country Status (29)

Country Link
US (6) US10799506B2 (OSRAM)
EP (3) EP4197530B1 (OSRAM)
JP (1) JP2018514523A (OSRAM)
KR (2) KR102750931B1 (OSRAM)
CN (2) CN107530292B (OSRAM)
AR (1) AR104257A1 (OSRAM)
AU (5) AU2016248017A1 (OSRAM)
BR (1) BR112017021283A2 (OSRAM)
CA (1) CA2982425C (OSRAM)
CL (1) CL2017002593A1 (OSRAM)
CO (1) CO2017010510A2 (OSRAM)
DK (1) DK3283058T3 (OSRAM)
EA (1) EA201792290A1 (OSRAM)
EC (1) ECSP17075052A (OSRAM)
ES (1) ES2938261T3 (OSRAM)
FI (1) FI3283058T3 (OSRAM)
HR (1) HRP20230053T1 (OSRAM)
HU (1) HUE061213T2 (OSRAM)
IL (1) IL254818A0 (OSRAM)
MX (1) MX2017013350A (OSRAM)
PE (1) PE20180035A1 (OSRAM)
PH (1) PH12017501820A1 (OSRAM)
PL (1) PL3283058T3 (OSRAM)
PT (1) PT3283058T (OSRAM)
SG (1) SG11201708084PA (OSRAM)
SI (1) SI3283058T1 (OSRAM)
TN (1) TN2017000422A1 (OSRAM)
TW (1) TW201642864A (OSRAM)
WO (1) WO2016166703A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3283058T3 (fi) * 2015-04-16 2023-03-01 Novartis Ag Ribosiklibitabletti
CA3048036A1 (en) 2018-07-02 2020-01-02 Apotex Inc Novel crystalline form of ribociclib succinate
CN114667147B (zh) 2019-08-26 2024-09-06 阿尔维纳斯运营股份有限公司 用四氢萘衍生物作为雌激素受体降解剂的治疗乳腺癌的方法
JP7681599B2 (ja) 2019-12-16 2025-05-22 ルネラ・バイオテック・インコーポレーテッド 選択的ｃｄｋ４／６阻害剤のがん治療薬
KR20220113986A (ko) 2019-12-16 2022-08-17 루넬라 바이오테크 인코포레이티드 선택적 cdk 4/6 억제제 암 치료제
WO2022029798A1 (en) * 2020-08-03 2022-02-10 Natco Pharma Limited Pharmaceutical compositions comprising ribociclib
US20230355578A1 (en) * 2020-09-29 2023-11-09 Laboratorios Silanes S.A. De C.V. Pharmaceutical combinations of statins and fibrates for the treatment and prevention of hyperlipidemias and cardiovascular disease
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
CN117396208A (zh) 2021-07-16 2024-01-12 达纳－法伯癌症研究所公司 细胞周期蛋白依赖性激酶4/6(cdk4/6)和ikzf2(helios)的小分子降解剂及其使用方法
TWI848533B (zh) 2022-01-25 2024-07-11 瑞士商諾華公司 瑞博西尼藥物組成物
EP4580631A1 (en) 2022-08-31 2025-07-09 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders
WO2024115680A1 (en) 2022-12-01 2024-06-06 Krka, D.D., Novo Mesto Ribociclib salts and formulations thereof
AU2024244511A1 (en) 2023-03-27 2025-09-25 Novartis Ag Method of treating early breast cancer with ribociclib in combination with an aromatase inhibitor
WO2025219830A1 (en) 2024-04-15 2025-10-23 Novartis Ag Pharmaceutical compositions of ribociclib

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5428812A (en) * 1977-08-09 1979-03-03 Yoshitomi Pharmaceut Ind Ltd Preparation of coated tablet
GB9414045D0 (en) 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
JP3672314B2 (ja) * 1994-07-12 2005-07-20 バーウィンド・ファーマスーティカル・サーヴィスィーズ・インコーポレーテッド 防湿性フィルム被覆材組成物、方法および被覆成形物
US6448323B1 (en) * 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
US8685980B2 (en) 2008-08-22 2014-04-01 Novartis Ag Pyrrolopyrimidine compounds and their uses
US20110070301A1 (en) * 2009-09-24 2011-03-24 Luber Joseph R Orally transformable tablets
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
SG192666A1 (en) * 2011-02-11 2013-09-30 Wista Lab Ltd Phenothiazine diaminium salts and their use
JP6226978B2 (ja) * 2012-07-13 2017-11-08 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体モジュレーター（ｓａｒｍ）によりアンドロゲン受容体（ａｒ）陽性乳癌を処置する方法
EP2742940B1 (en) * 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
EP2934515B1 (en) * 2012-12-20 2018-04-04 Novartis AG A pharmaceutical combination comprising binimetinib
UA118846C2 (uk) * 2013-03-21 2019-03-25 Новартіс Аг Комбінована терапія
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
FI3283058T3 (fi) * 2015-04-16 2023-03-01 Novartis Ag Ribosiklibitabletti
CN109953966A (zh) * 2017-12-26 2019-07-02 天津耀辰实业发展有限公司 一种含有瑞博西尼的药物组合物及其制备方法
JP7347388B2 (ja) 2020-09-25 2023-09-20 信越化学工業株式会社 紫外線硬化型有機変性シリコーン組成物および硬化物

Also Published As

Publication number Publication date
SI3283058T1 (sl) 2023-03-31
US20250090531A1 (en) 2025-03-20
CN115554257A (zh) 2023-01-03
PT3283058T (pt) 2023-02-03
KR20170137101A (ko) 2017-12-12
CA2982425A1 (en) 2016-10-20
MX2017013350A (es) 2018-01-25
US20250127785A1 (en) 2025-04-24
US20250134893A1 (en) 2025-05-01
CL2017002593A1 (es) 2018-05-18
AU2019201929B2 (en) 2020-07-09
PL3283058T3 (pl) 2023-03-20
JP2018514523A (ja) 2018-06-07
TN2017000422A1 (en) 2019-01-16
EP4197530B1 (en) 2025-11-12
EP4197530A1 (en) 2023-06-21
US20230104792A1 (en) 2023-04-06
EP3283058A1 (en) 2018-02-21
AU2022215155A1 (en) 2022-09-01
EP4620458A3 (en) 2025-10-22
CO2017010510A2 (es) 2018-03-20
ES2938261T3 (es) 2023-04-05
AU2016248017A1 (en) 2017-10-19
BR112017021283A2 (pt) 2018-06-26
PE20180035A1 (es) 2018-01-09
CN107530292B (zh) 2022-11-01
PH12017501820A1 (en) 2018-04-23
EP3283058B1 (en) 2022-11-16
HUE061213T2 (hu) 2023-05-28
US20200390771A1 (en) 2020-12-17
DK3283058T3 (da) 2023-02-13
US10799506B2 (en) 2020-10-13
KR102750931B1 (ko) 2025-01-09
KR20250009572A (ko) 2025-01-17
AU2022215155B2 (en) 2024-08-01
ECSP17075052A (es) 2018-02-28
CA2982425C (en) 2023-10-31
AU2019201929A1 (en) 2019-04-11
CN107530292A (zh) 2018-01-02
AU2020250190A1 (en) 2020-11-05
EP4620458A2 (en) 2025-09-24
HRP20230053T1 (hr) 2023-03-03
WO2016166703A1 (en) 2016-10-20
AR104257A1 (es) 2017-07-05
TW201642864A (zh) 2016-12-16
SG11201708084PA (en) 2017-10-30
AU2024227794A1 (en) 2024-11-21
US12419894B2 (en) 2025-09-23
US20180071292A1 (en) 2018-03-15
EA201792290A1 (ru) 2018-02-28
IL254818A0 (en) 2017-12-31
US12064434B2 (en) 2024-08-20

Similar Documents

Publication Publication Date Title
FI3283058T3 (fi) Ribosiklibitabletti
CN104258408B (zh) 易服用性固体制剂
HRP20190936T1 (hr) Amorfni letermovir i njegove krute farmaceutske formulacije za oralnu primjenu
IL292262B2 (en) Formulation of an oral administration form of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid
FI3702351T3 (fi) MEK-inhibiittorin käsittävä koostumus
NZ753904A (en) Compositions and methods for treating anemia
RU2016103753A (ru) Лечение воспалительных повреждений при розациа с помощью ивермектина
ES2435943T3 (es) Formulaciones de vildagliptina
US9555121B2 (en) Composition for forming complex, complex formed therefrom, and composition for oral administration including said complex
JP2013530206A5 (OSRAM)
WO2013098268A3 (en) Tablets and dry-coated agents
JP2016512493A5 (OSRAM)
PH12013502300A1 (en) Compound dual-release capsule formulation comprised of bromodihydroartemisinin and fe2+ agent
CN102935078A (zh) 一种布洛芬口腔分散膜剂
JP2019196395A (ja) 縮合アミノジヒドロチアジン誘導体の医薬組成物
ES2706994T3 (es) Composición farmacéutica de liberación prolongada de administración oral que contiene clorhidrato de hidromorfona
WO2012067482A3 (es) COMPOSICIÓN FARMACÉUTICA ADAPTADA PARA ADMINISTRARSE ORALMENTE Y PROCESO PARA SU PREPARACIÓN, PARA PREVENCIÓN Y TRATAMIENTO DEL SÍNDROME DE INTESTINO IRRITABLE, A BASE DE UN MODIFICADOR DE LA MOTILIDAD INTESTINAL Y α-D-GALAGTOSIDASA
MX2015015681A (es) Composicion farmaceutica que comprende fingolimod.
MX2021003355A (es) Composicion farmaceutica que contiene fosfato, tartrato de alquilcarbamoil naftaleniloxioctenoil hidroxiamida o una combinacion de ellos y metodo de preparacion de la misma.
WO2013054178A8 (en) Extended release pharmaceutical compositions containing carmabazepine
TWI589292B (zh) 用於控管噁心及嘔吐之組合物
WO2009063320A2 (es) Composición farmacéutica sólida de didanosina
WO2021084562A2 (en) Antibiotic with modified side effects for hospitalized patients (new protocol, new compound drug)
RU2015140501A (ru) Фармацевтические композиции на основе донепезила, характеризующиеся специфическим профилем растворимости in vitro или фармакокинетическими параметрами
JP2013533874A5 (OSRAM)